The immunopathogenesis of sepsis

Nature

Volumn 420, Issue 6917, 2002, Pages 885-891

  Cohen, Jonathan ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; IMMUNOLOGY; TISSUE;

BACTERIAL-HOST INFECTIONS; SEPSIS;

PATHOLOGY;

BLOOD CLOTTING FACTOR 5 LEIDEN; CD14 ANTIGEN; CHEMOKINE; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIPOPOLYSACCHARIDE BINDING PROTEIN; LYMPHOTOXIN; OXYGEN RADICAL; TISSUE PLASMINOGEN ACTIVATOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

MEDICINE;

BLOOD CLOTTING; HOST PARASITE INTERACTION; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; TISSUE INJURY;

ANIMALS; BACTERIAL INFECTIONS; GENETIC PREDISPOSITION TO DISEASE; HOST-PARASITE RELATIONS; HUMANS; INFLAMMATION; MULTIPLE ORGAN FAILURE; POLYMORPHISM, GENETIC; SEPSIS; SIGNAL TRANSDUCTION;

BACTERIA (MICROORGANISMS);

EID: 0037180768     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature01326     Document Type: Review

References (74)

1. Angus D.C. et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310 (2001).
2. Alberti, C. et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 28, 108-121 (2002).
3. Janeway, C. A. Jr & Medzhitov, R. Introduction: The role of innate immunity in the adaptive immune response. Semin. Immunol. 10, 349-350 (1998).
4. Seydel, U., Oikawa, M., Fukase, K., Kusumoto, S. & Brandenburg, K. Intrinsic conformation of lipid A is responsible for agonistic and antagonistic activity. Eur. J. Biochem. 267, 3032-3039 (2000).
5. Majcherczyk, P. A. et al. Digestion of Streptococcuss pneumoniae cell walls with its major peptidoglycan hydrolase releases branched stem peptides carrying proinflammatory activity. J. Biol. Chem. 274, 12537-12543 (1999).
6. Morath, S., Geyer, A. & Hartung, T. Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J. Exp. Med. 193, 393-397 (2001).
7. Wang, J. E. et al. Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect Immun. 68, 3965-3970 (2000).
8. Lavoie, P. M., Thibodeau, J., Erard, F. & Sekaly, R. P. Understanding the mechanism of action of bacterial superantigens from a decade of research. Immunol. Rev. 168, 257-269 (1999).
9. Papageorgiou, A. C. & Acharya, K. R. Microbial superantigens: From structure to function. Trends Microbiol. 8, 369-375 (2000).
10. Kotb, M. Bacterial pyrogenic exotoxins as superantigens. Clin. Microbiol. Rev. 8, 411-426 (1995).
11. Norrby-Teglund, A. et al. Evidence for superantigen involvement in severe group A streptococcal tissue infections. J. Infect. Dis. 184, 853-860 (2001).
12. Muller-Alouf, H. et al. Pyrogenicity and cytokine-inducing properties of Streptococcus pyogenes superantigens: Comparative study of streptococcal mitogenic exotoxin Z and pyrogenic exotoxin A. Infect. Immun. 69, 4141-4145 (2001).
13. Unnikrishnan, M. et al. The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of Streptococcus pyogenes. J. Immunol. 169, 2561-2569 (2002).
14. Dinges, M. M. & Schlievert, P. M. Role of T cells and gamma interferon during induction of hypersensitivity to lipopolysaccharide by toxic shock syndrome toxin 1 in mice. Infect. Immun. 69, 1256-1264 (2001).
15. Eaves-Pyles, T. et al. Flagellin, a novel mediator of salmonella-induced epithelial activation and systemic inflammation: IκBα degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction. J. Immunol. 166, 1248-1260 (2001).
16. Herwald, H. et al. Activation of the contact-phase system on bacterial surfaces - A clue to serious complications in infectious diseases. Nature Med. 4, 298-302 (1998).
17. Sparwasser, T. et al. Bacterial DNA causes septic shock. Nature 386, 336-337 (1997).
18. Bauer, S. et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad. Sci. USA 98, 9237-9242 (2001).
19. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J. & Mathison, J. C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249, 1431-1433 (1990).
20. Pugin, J. et al. CD14 is a pattern recognition receptor. Immunity 1, 509-516 (1994).
21. Devitt, A. et al. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392, 505-509 (1998).
22. Yu, B., Hailman, E. & Wright, S. D. Lipopolysaccharide binding protein and soluble CD 14 catalyze exchange of phospholipids. J. Clin. Invest. 99, 315-324 (1997).
23. Landmann, R. et al. Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J. Infect. Dis. 171, 639-644 (1995).
24. Leturcq, D. J. et al. Antibodies against CD14 protect primates from endotoxin-induced shock. J. Clin. Invest. 98, 1533-1538 (1996).
25. Aderem, A. & Ulevitch, R. J. Toll-like receptors in the induction of the innate immune response. Nature 406, 782-787 (2000).
26. Vasselon, T. & Detmers, P. A. Toll receptors: A central element in innate immune responses. Infect. Immun. 70, 1033 (2002).
27. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C. A. Jr A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997).
28. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282, 2085-2088 (1998).
29. Opal, S. M. & Huber, Ch. Bench-to-bedside review: Toll-like receptors and their role in septic shock. Crit. Care 6, 125-136 (2002).
30. Takeuchi, O. et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11, 443-451 (1999).
31. Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099-1103 (2001).
32. Shimazu, R. et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189, 1777-1782 (1999).
33. Nagai, Y. et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nature Immunol. 3, 667-672 (2002).
34. Ozinsky, A. et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl Acad. Sci. USA 97, 13766-13771 (2000).
35. Lorenz, E., Mira, J. P., Cornish, K. L., Arbour, N. C. & Schwartz, D. A. A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect. Immun. 68, 6398-6401 (2000).
36. Lorenz, E., Mira, J. P., Frees, K. L. & Schwartz, D. A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 162, 1028-1032 (2002).
37. Bowie, A. & O'Neill, L. A. The interleukin-1 receptor/Toll-like receptor superfamily: Signal generators for pro-inflammatory interleukins and microbial products. J. Leukoc. Biol. 67, 508-514 (2000).
38. Werner, T. et al. A family of peptidoglycan recognition proteins in the fruit fly Drosophila melanogaster. Proc. Natl Acad. Sci. USA 97, 13772-13777 (2000).
39. Liu, C., Xu, Z., Gupta, D. & Dziarski, R. Peptidoglycan recognition proteins: A novel family of four human innate immunity pattern recognition molecules. J. Biol. Chem. 276, 34686-34694 (2001).
40. Michel, T., Reichhart, J. M., Hoffmann, J. A. & Royet, J. Drosophila Toll is activated by gram-positive bacteria through a circulating peptidoglycan recognition protein. Nature 4l4, 756-759 (2001).
41. Gottar, M. et al. The Drosophila immune response against Gram-negative bacteria is mediated by a peptidoglycan recognition protein. Nature 416, 640-644 (2002).
42. Ramet, M., Manfruelli, P., Pearson, A., Mathey-Prevot, B. & Ezekowitz, R. A. Functional genomic analysis ofphagocytosis and identification of a Drosophila receptor for E. coli. Nature 416, 644-648 (2002).
43. Choe, K. M., Werner, T., Stoven, S., Hultmark, D. & Anderson, K. V. Requirement for a peptidoglycan recognition protein (PGRP) in Relish activation and antibacterial immune responses in Drosophila. Science 296, 359-362 (2002).
44. Bouchon, A., Dietrich, J. & Colonna, M. Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164, 4991-4995 (2000).
45. Bouchon, A., Facchetti, F., Weigand, M. A. & Colonna, M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410, 1103-1107 (2001).
46. Inohara, N., Ogura, Y., Chen, F. F., Muto, A. & Nunez, G. Human Nod 1 confers responsiveness to bacterial lipopolysaccharides. J. Biol. Chem. 276, 2551-2554 (2001).
47. Inohara, N., Ogura,Y. & Nunez, G. Nods: A family of cytosolic proteins that regulate the host response to pathogens. Curr. Opin. Microbiol. 5, 76-80 (2002).
48. Hampe, J. et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: A cohort study. Lancet 359, 1661-1665 (2002).
49. Dinarello, C. A. Proinflammatory and anti-inflammatory cytokine as mediators in the pathogenesis of septic shock. Chest 112, 321S-329S (1997).
50. Cohen, J. Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. Br. Med. Bull. 55, 212-226 (1999).
51. Yang, H., Wang, H. & Tracey, K. J. HMG-1 rediscovered as a cytokine. Shock 15, 247-253 (2001).
52. Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999).
53. Bozza, M. et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189, 341-346 (1999).
54. Calandra, T. et al. Protection from septic shock by neutralization ofmacrophage migration inhibitory factor. Nature Med. 6, 164-170 (2000).
55. Calandra, T., Spiegel, L. A., Metz, C. N. & Bucala, R. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc. Natl Acad. Sci. USA 95, 11383-11388 (1998).
56. Calandra, T. et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377, 68-71(1995).
57. Bosisio, D. et al. Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood 99, 3427-3431 (2002).
58. Levi, M. & ten Cate, H. Disseminated intravascular coagulation. N. Engl. J. Med. 341, 586-592 (1999).
59. Van der Poll, T., de Jonge, E., Levi, M. & van Deventer, S. J. Pathogenesis of DIC in sepsis. Sepsis 3, 103-110 (1999).
60. Okajima, K. Regulation of inflammatory responses by natural anticoagulants. Immunol. Rev. 184, 258-274 (2002).
61. Riewald, M., Petrovan, R. J., Donner, A., Mueller, B. M. & Ruf, W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880-1882 (2002).
62. Faust, S. N. et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med. 345, 408-416 (2001).
63. Hotchkiss, R. S. et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. CareMed. 27, 1230-1251 (1999).
64. + T lymphocytes in humans. J. Immonul. 166, 6952-6963 (2001).
65. Hotchkiss, R. S. et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl Acad. Sci. USA 96, 14541-14546 (1999).
66. Döcke, W.-D. et al. Monocyte deactivation in septic patients: Restoration by 1FN-γ treatment. Nature Med. 3, 678-681 (1997).
67. Stuber, F. Effects of genomic polymorphisms on the course of sepsis: Is there a concept for gene therapy? J. Am. Soc. Nephrol. 12(Suppl. 17), S60-S64 (2001).
68. Landry, D. W. & Oliver, J. A. The pathogenesis of vasodilatory shock. N. Engl. J. Med. 345, 588-595 (200t).
69. Brealey, D. et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360, 219-223 (2002).
70. Rivers, E. et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345, 1368-1377 (2001).
71. Van den Berghe, G. et al. Intensive insulin therapy in critically ill patients. N. Engl. J. Med. 345, 1359-1367 (2001).
72. Annane, D. et al. Effects of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. J. Am. Med. Assoc. 288, 862-871 (2002).
73. Bernard, G. R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
74. Bochkov, V. N. et al. Protective role ofphospholipid oxidation products in endotoxin-induced tissue damage. Nature 419, 77-81 (2002).